Literature DB >> 26322413

Nebulization of Poractant alfa via a vibrating membrane nebulizer in spontaneously breathing preterm lambs with binasal continuous positive pressure ventilation.

Matthias C Hütten1,2, Elke Kuypers1, Daan R Ophelders1, Maria Nikiforou1, Reint K Jellema1, Hendrik J Niemarkt1, Carola Fuchs3, Markus Tservistas3, Roberta Razetti4, Federico Bianco4, Boris W Kramer1.   

Abstract

BACKGROUND: Surfactant replacement therapy is the gold standard treatment of neonatal respiratory distress (RDS). Nebulization is a noninvasive mode of surfactant administration. We administered Poractant alfa (Curosurf) via a vibrating perforated membrane nebulizer (eFlow Neonatal Nebulizer) to spontaneously breathing preterm lambs during binasal continuous positive pressure ventilation (CPAP).
METHODS: Sixteen preterm lambs were operatively delivered at a gestational age of 133 ± 1 d (term ~150 d), and connected to CPAP applied via customized nasal prongs. Nebulization was performed (i) with saline or (ii) with surfactant for 3 h in humidified or (iii) nonhumidified air, and with surfactant (iv) for 60 min or (v) for 30 min. We measured arterial oxygenation, lung gas volumes and surfactant pool size and deposition.
RESULTS: Nebulization of surfactant in humidified air for 3 h improved oxygenation and lung function, and surfactant was preferentially distributed to the lower lung lobes. Shorter nebulization times and 3 h nebulization in dry air did not show these effects. Nebulized surfactant reached all lung lobes, however the increase of surfactant pool size missed statistical significance.
CONCLUSION: Positive effects of surfactant nebulization to spontaneously breathing preterm lambs depend on treatment duration, surfactant dose, air humidity, and surfactant distribution within the lung.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26322413     DOI: 10.1038/pr.2015.165

Source DB:  PubMed          Journal:  Pediatr Res        ISSN: 0031-3998            Impact factor:   3.756


  42 in total

1.  The non-intubated, spontaneously breathing, continuous positive airway pressure (CPAP) ventilated pre-term lamb: a unique animal model.

Authors:  D K Rahmel; G Pohlmann; P Iwatschenko; J Volland; S Liebisch; H Kock; L Mecklenburg; C Maurer; J Kemkowski; F J H Taut
Journal:  Reprod Toxicol       Date:  2012-05-29       Impact factor: 3.143

2.  Aerosolized surfactant treatment of preterm lambs.

Authors:  J F Lewis; M Ikegami; A H Jobe; B Tabor
Journal:  J Appl Physiol (1985)       Date:  1991-02

3.  Pulmonary distribution of particles given by intratracheal instillation or by aerosol inhalation.

Authors:  J D Brain; D E Knudson; S P Sorokin; M A Davis
Journal:  Environ Res       Date:  1976-02       Impact factor: 6.498

4.  Tidal volume, recruitment and compliance in HFOV: same principles, different frequency.

Authors:  J Jane Pillow
Journal:  Eur Respir J       Date:  2012-08       Impact factor: 16.671

5.  A randomized, controlled trial of poractant alfa versus beractant in the treatment of preterm infants with respiratory distress syndrome.

Authors:  Evrim Alyamac Dizdar; Fatma Nur Sari; Cumhur Aydemir; Serife Suna Oguz; Omer Erdeve; Nurdan Uras; Ugur Dilmen
Journal:  Am J Perinatol       Date:  2011-11-21       Impact factor: 1.862

Review 6.  Clinical trials of natural surfactant extract in respiratory distress syndrome.

Authors:  C E Mercier; R F Soll
Journal:  Clin Perinatol       Date:  1993-12       Impact factor: 3.430

7.  Betamethasone for lung maturation: testing dose and formulation in fetal sheep.

Authors:  Alan H Jobe; Timothy J M Moss; Ilias Nitsos; Machiko Ikegami; Suhas G Kallapur; John P Newnham
Journal:  Am J Obstet Gynecol       Date:  2007-11       Impact factor: 8.661

Review 8.  Nebulised surfactant in preterm infants with or at risk of respiratory distress syndrome.

Authors:  Mohamed E Abdel-Latif; David A Osborn
Journal:  Cochrane Database Syst Rev       Date:  2012-10-17

9.  Pulmonary vascular endothelial growth factor expression and disaturated phospholipid content in a chicken model of hypoxia-induced fetal growth restriction.

Authors:  Jasper V Been; Bea Zoer; Nico Kloosterboer; Carolina G A Kessels; Luc J I Zimmermann; J Freek van Iwaarden; Eduardo Villamor
Journal:  Neonatology       Date:  2009-10-28       Impact factor: 4.035

10.  Mortality in preterm infants with respiratory distress syndrome treated with poractant alfa, calfactant or beractant: a retrospective study.

Authors:  R Ramanathan; J J Bhatia; K Sekar; F R Ernst
Journal:  J Perinatol       Date:  2011-09-01       Impact factor: 2.521

View more
  14 in total

Review 1.  Surfactant for Respiratory Distress Syndrome: New Ideas on a Familiar Drug with Innovative Applications.

Authors:  H J Niemarkt; M C Hütten; Boris W Kramer
Journal:  Neonatology       Date:  2017-05-25       Impact factor: 4.035

2.  Generation of High Concentrations of Respirable Solid-Phase Aerosols from Viscous Fluids.

Authors:  Xin Heng; Donovan B Yeates
Journal:  Aerosol Sci Technol       Date:  2018-07-30       Impact factor: 2.908

3.  Non-invasive ventilation and surfactant treatment as the primary mode of respiratory support in surfactant-deficient newborn piglets.

Authors:  Carmen Rey-Santano; Victoria E Mielgo; Miguel Angel Gomez-Solaetxe; Francesca Ricci; Federico Bianco; Fabrizio Salomone; Begoña Loureiro; Jon López de Heredia Y Goya
Journal:  Pediatr Res       Date:  2018-02-14       Impact factor: 3.756

4.  Development of a High-Dose Infant Air-Jet Dry Powder Inhaler (DPI) with Passive Cyclic Loading of the Formulation.

Authors:  Connor Howe; Mohammad A M Momin; Ghali Aladwani; Michael Hindle; P Worth Longest
Journal:  Pharm Res       Date:  2022-10-17       Impact factor: 4.580

5.  Physiological, Biochemical, and Biophysical Characterization of the Lung-Lavaged Spontaneously-Breathing Rabbit as a Model for Respiratory Distress Syndrome.

Authors:  Francesca Ricci; Chiara Catozzi; Xabier Murgia; Brenda Rosa; Davide Amidani; Luca Lorenzini; Federico Bianco; Claudio Rivetti; Silvia Catinella; Gino Villetti; Maurizio Civelli; Barbara Pioselli; Carlo Dani; Fabrizio Salomone
Journal:  PLoS One       Date:  2017-01-06       Impact factor: 3.240

Review 6.  The Future of Bronchopulmonary Dysplasia: Emerging Pathophysiological Concepts and Potential New Avenues of Treatment.

Authors:  Jennifer J P Collins; Dick Tibboel; Ismé M de Kleer; Irwin K M Reiss; Robbert J Rottier
Journal:  Front Med (Lausanne)       Date:  2017-05-22

Review 7.  Surfactant replacement therapy: from biological basis to current clinical practice.

Authors:  Roland Hentschel; Kajsa Bohlin; Anton van Kaam; Hans Fuchs; Olivier Danhaive
Journal:  Pediatr Res       Date:  2020-01-11       Impact factor: 3.756

8.  Nebulized Poractant Alfa Reduces the Risk of Respiratory Failure at 72 Hours in Spontaneously Breathing Surfactant-Deficient Newborn Piglets.

Authors:  Carmen Rey-Santano; Victoria E Mielgo; Miguel Angel Gomez-Solaetxe; Federico Bianco; Fabrizio Salomone; Begoña Loureiro
Journal:  Crit Care Med       Date:  2020-06       Impact factor: 7.598

9.  Dose-Response Study on Surfactant Nebulization Therapy During Nasal Continuous Positive Airway Pressure Ventilation in Spontaneously Breathing Surfactant-Deficient Newborn Piglets.

Authors:  Carmen Rey-Santano; Victoria Mielgo; Miguel Angel Gomez-Solaetxe; Francesca Ricci; Federico Bianco; Fabrizio Salomone; Begoña Loureiro
Journal:  Pediatr Crit Care Med       Date:  2020-07       Impact factor: 3.624

10.  Surfactant replacement therapy in combination with different non-invasive ventilation techniques in spontaneously-breathing, surfactant-depleted adult rabbits.

Authors:  Francesca Ricci; Costanza Casiraghi; Matteo Storti; Francesco D'Alò; Chiara Catozzi; Roberta Ciccimarra; Francesca Ravanetti; Antonio Cacchioli; Gino Villetti; Maurizio Civelli; Xabi Murgia; Virgilio Carnielli; Fabrizio Salomone
Journal:  PLoS One       Date:  2018-07-12       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.